Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy

Melanoma Research

Volumn 23, Issue 6, 2013, Pages 498-501

  Pintova, Sofya ^a   Sidhu, Harleen ^b   Friedlander, Philip A ^a   Holcombe, Randall F ^a  

^a Department of Hematology and Medical Oncology ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cytotoxic T lymphocyte associated antigen 4 antibody; ipilimumab; metastatic melanoma; neutrophilic dermatosis; Sweet's syndrome

Indexed keywords

CREATININE; DIPHENHYDRAMINE; IPILIMUMAB; METHYLPREDNISOLONE; PARACETAMOL; PETHIDINE; STEROID; UREA;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFUSION; CREATININE BLOOD LEVEL; DIZZINESS; DYSPNEA; ENTEROCOLITIS; FEMALE; FEVER; HAND RASH; HEADACHE; HEMATURIA; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; LIVER METASTASIS; LUNG METASTASIS; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NEUTROPHIL CHEMOTAXIS; OLIGURIA; PATIENT TRANSPORT; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RIGOR; SKIN BIOPSY; STEREOTACTIC BODY RADIATION THERAPY; UREA NITROGEN BLOOD LEVEL;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOPSY; ENTEROCOLITIS; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM METASTASIS; NEUTROPHILS; RENAL INSUFFICIENCY; SKIN NEOPLASMS; STEROIDS; SWEET SYNDROME;

EID: 84887621573     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000017     Document Type: Article

References (21)

1. Dabade TS, Davis MD. Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet's syndrome). Dermatol Ther 2011; 24:273-284
2. Anzalone CL, Cohen PR. Acute febrile neutrophilic dermatosis (Sweet's syndrome). Curr Opin Hematol 2013; 20:26-35
3. Sanchez Conejo-Mir J, Perez Bernal A, Camacho F. Acute neutrophilic febrile dermatosis (Sweet syndrome) associated with melanoma [article in Spanish]. Med Cutan Ibero Lat Am 1990; 18:155-158
4. Monfort JB, Pages C, Schneider P, Neyns B, Comte C, Bagot M, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res 2012; 22:399-401
5. Zimmer L, Livingstone E, Hillen U, Domkes S, Becker A, Schadendorf D. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012; 148:357-361
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723
7. Robert C, Thomas L, Bondarenko I, O'Day S, MD JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526
8. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA- 4 antibodies across clinical indications. Semin Oncol 2010; 37:499-507
9. Minkis K, Aksentijevich I, Goldbach-Mansky R, Magro C, Scott R, Davis JG, et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol 2012; 148:747-752
10. Pappas-Taffer L, Rosenbach M, Chu EY. The cutaneous side effects of selective BRAF inhibitors and anti-CTLA4 agents: the growing role of the dermatologist in the management of patients with metastatic melanoma. Curr Dermatol Rep 2013; 2:84-100
11. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105:3005-3010
12. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic Tlymphocyte- associated antigen 4. J Clin Oncol 2006; 24:2283-2289
13. Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol 1996; 34:918-923
14. Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol 1994; 130:77-81
15. Reuss-Borst MA, Muller CA,Waller HD. The possible role of G-CSF in the pathogenesis of Sweet's syndrome. Leuk Lymphoma 1994; 15 (3-4):261-264
16. Kawakami T, Ohashi S, Kawa Y, Takahama H, Ito M, Soma Y, et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of Sweet syndrome and patients with active Behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol 2004; 140:570-574
17. Reuss-Borst MA, Pawelec G, Saal JG, Horny HP, Muller CA,Waller HD. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol 1993; 84:356-358
18. Marzano AV, Cugno M, Trevisan V, Fanoni D, Venegoni L, Berti E, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol 2010; 162:100-107
19. Giasuddin AS, El-Orfi AH, Ziu MM, El-Barnawi NY. Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol 1998; 39:940-943
20. Ledezma B. Ipilimumab for advanced melanoma: a nursing perspective. Oncol Nurs Forum 2009; 36:97-104
21. Sapoznik S, Hammer O, Ortenberg R, Besser MJ, Ben-Moshe T, Schachter J, et al. Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol 2012; 2012:818214.